The first generation EGFR kinase inhibitors, such as Gefitinib, have shown great clinical efficacy for the EGFR mutant driven NSCLC, but after a period of treatment, most patients will develop EGFR T790M-induced drug resistance [4]. Here, EGFR is linked to non-small cell lung carcinoma.